Corrigendum to 'Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy' [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]

Subjects

Subjects :

medicine.medical_specialty
Physical medicine and rehabilitation
Neurology
business.industry
Duchenne muscular dystrophy
Pediatrics, Perinatology and Child Health
medicine
Neurology (clinical)
Open label
medicine.disease
business
Genetics (clinical)

Details

ISSN :

09608966

Volume :

31

Database :

OpenAIRE

Journal :

Neuromuscular Disorders

Accession number :

edsair.doi...........8143a42ed208dcffabb620ec8bc9d7ad

Full Text :

https://doi.org/10.1016/j.nmd.2021.01.001